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The rationale behind active treatment and ablation in asymptomatic WPW is to prevent sudden 
cardiac death (SCD). SCD in asymptomatic WPW syndrome has been noted to vary from 0.15 
to  0.39% over  3-10  years  follow  up  [1,2].                                        
SCD  happens  in  WPW  in  relation  to  rapid  pre-excited  atrial  fibrillation  (AF)  with  fast 
ventricular response.   It happens in 50% of SCD as the first manifestation. Hence, though the 
incidence  of SCD is  low in WPW, the same is  avoidable in  suitably selected cases.  It  can 
presently  be  taken  care  of,  by  radiofrequency  (RF)  ablation  of  the  bypass  tract  without 
significant  morbidity.                                       
What then are the criteria to select patients of Asymptomatic WPW who may be predisposed to 
SCD? The markers identified for SCD include: 1. Anterograde effective refractory period of 
accessory pathway (APERP) 240- 250ms; (on isoproternol APERP <200ms?)  2. Shortest Pre-
excited  RR  interval (SPERRI) less than 250ms during or induced AF. 3. Multiple accessory 
pathways   4. Ebsteins anomaly 5. Familial WPW syndrome. The Non invasive parameters of a 
presumed long refractory period of bypass tract (>250ms) include: 1. Intermittent pre-excitation. 
2. Disappearance of pre-excitation during exercise and 3. Disappearance of pre-excitation with 
procainamide.  The predictive value of the non invasive parameters is low and when combined 
with  the low risk of  RF ablation,  most  electrophysiologists  rely  on invasive  testing to  risk 
stratify  asymptomatic  patients.  In  a  European  survey   44% of  EP centers  perform invasive 
approach as the first line approach [3] in asymptomatic WPW.                                   
Regardless of how the EP protocol is set, one of the specific parameter taken is anterograde ERP 
<240ms at baseline to decide RF ablation. Additional parameters include Minimum RR interval 
in  AF:  SPERRI <250ms,  and AF induction.  Considering  all  boundary  parameters,  the  best 
binary discriminators are  APERP <240ms at baseline and SPERRI<250ms, which we follow at 
our centre. In perhaps the best prospective follow up study in children age 8-12 yrs, with a 
follow up  of  57  months,  Pappone  et  al  [4-7]  identified  the  following  1.  Tachyarrhythmia 
inducibility. 2. APERP <240ms 3. Multiple accessory pathways; as independent risk factors for 
life threatening events. Of these APERP and multiple bypass tracts were independent predictors 
by  multivariate  analysis.                                           
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The  "PACES /HRS Consensus  statement  on  the  management  of  the  Asymptomatic  Young 
Patient  with  a  WPW Electrocardiographic  pattern"  published  this  week  [9]  has  noted  that  
SPERRI  and APERP remain important  baseline parameters in risk stratifying asymptomatic 
WPW patients, with high sensitivity and negative predictive value; but with low specificity and 
positive  predictive  value.  They have  observed  that  SPERRI <250ms is  superior  to  APERP 
<240ms  in  discriminating  patients  at  risk  for  SCD  or  VF.  The  consensus  statement  has 
recommended that young patients with SPERRI <250ms in AF are at increased risk for SCD 
and RF Catheter ablation is a reasonable option ( Class IIA, Level of evidence B/C ).          
Therefore the most important binary parameters to the invasive Electrophysiologist is SPERRI 
<250ms and APERP < 240ms at baseline (without Isoproternol) to decide RF Ablation.          
The important question raised in this issue by Oliver C et al in this issue of the journal [8] is the 
stability of this parameter of APERP. Does it change temporally at two different occasions? 
Does the APERP assessed by isoproternol also change with time? In short: is the parameter of 
baseline APERP stable and to put  it  clinically,  can it  be accepted as a value to decide RF 
ablation  or  otherwise  in  asymptomatic  WPW.                                   
The changes of baseline APERP temporally in the basal state, as noted by the authors, [8] are 
variable,  but  not  significant  enough,  to  warrant  different  approaches  or  multiple  studies  to 
decide the need for RF ablation.  A  minor group of patients (15% had a APERP <240ms at the 
second study)  will be left out with an ambiguous decision for medical follow up if the first 
baseline  APERP is  chosen.  But  it  is  also  likely  that  this  group  will  be  picked  for  further 
evaluation  and  not  necessarily  present  as  SCD.                             
The  response  to  APERP  on  isoproternol  has  been  studied  by  multiple  authors;  though 
acceptance  of  a  standard  value  has  not  been  universally  agreed  upon.  A value  of  APERP 
<200ms on isoproternol has been noted as a cut off value, but the dose of the drug has ranged 
from 1-20µg per minute. The authors [8] have noted significant variations in the APERP values 
temporally after isoproternol infusion. A significant group (with APERP >200ms) at first study- 
33% had APERP <200ms at the second study. The conclusion would necessarily imply that the 
ERP values on isoproternol cannot be relied for assessing risk in the asymptomatic WPW. The 
variations are likely to be related to the status of the autonomic system that will modulate the 
electrophysiological properties of the bypass tract and the AV Node.                          
I  would  like  to  conclude  by  noting  that  APERP  estimations  are  temporally  variable.  The 
variations  are  more  pronounced  during  Isoproternol  infusion.  As  a  matter  of  fact  all  EP 
parameters ranging from Venricular ERP to VT Inducibility are temporally variable; what is 
important is to know the significance of a baseline parameter in relation to the natural history of 
the disease. On the background of the natural history studies by previous authors, the variations 
in the basal state are acceptable and a value of  APERP <240ms  can serve as a binary cut off 
value to indicate and select a potentially high risk group that can undergo RF ablation to reduce 
Sudden  Cardiac  Death.  EP  studies  of  APERP  on  isoproternol  show  significant  variations 
temporally and cannot be relied upon as a sole predictor of future risk, independently; however 
it can contribute to the basal study.  Based on the Consensus Statement and Recommendations 
SPERRI <250 ms can serve as a parameter to select patients for catheter ablation [9] and is 
superior to APERP <240ms at baseline. Other risk factors too, as noted above, may be taken 
into  consideration  in  the  decision  making  process.  The  basal  APERP  study,  inspite  of  its 
limitations, can   guide the decision to ablate or not in Asymptomatic WPW.                 
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